From the Journals

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection

Share

Advancements in diagnostic, prognostic, and predictive biomarkers are transforming the management of colorectal cancer (CRC). Grounded in a narrative review by Alfonso Agüera-Sánchez and colleagues, established markers like KRAS mutations and MSI status are foundational in personalized CRC therapy. Emerging biomarkers, including circulating tumor DNA and microbiome analysis, are enhancing noninvasive detection techniques. The integration of multi-omics is shaping prognosis and treatment adaptation, with ongoing studies aimed at refining clinical outcomes. The future emphasizes the urgent need for validation and standardization.

Original Source(s)

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection

  • by Julia Cipriano, MS, CMPP

  • February 6, 2026

  • 5 min

Related Content

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

Immunoscore Refines CRC Prognosis, Therapy

Despite a strong evidence base, the assay has not been widely implemented in routine clinical practice.

New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer

The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.